Edition:
United States

Egalet Corp (EGLT.OQ)

EGLT.OQ on NASDAQ Stock Exchange Capital Market

0.36USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$0.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
89,500
52-wk High
$1.58
52-wk Low
$0.34

Latest Key Developments (Source: Significant Developments)

Egalet Announces A Large Regional Health Plan
Wednesday, 28 Feb 2018 06:02am EST 

Feb 28 (Reuters) - Egalet Corp ::EGALET ANNOUNCES A LARGE REGIONAL HEALTH PLAN PLACED ARYMO® ER AND SPRIX® NASAL SPRAY IN PREFERRED FORMULARY POSITIONS.EGALET - A NORTHEAST REGIONAL HEALTH PLAN PLACED ARYMO ER EXTENDED-RELEASE TABLETS FOR ORAL USE ONLY -CII & SPRIX NASAL SPRAY.  Full Article

Egalet Says Received Notice From Teva Pharmaceuticals USA Of ANDA Submission For Approval To Market Generic Version Of Arymo ER Extended-Release Tablets
Friday, 23 Feb 2018 05:39pm EST 

Feb 23 (Reuters) - Egalet Corp ::EGALET - CO, UNIT RECEIVED NOTICE FROM TEVA PHARMACEUTICALS USA OF ANDA SUBMISSION FOR APPROVAL TO MARKET GENERIC VERSION OF ARYMO ER EXTENDED-RELEASE TABLETS.EGALET SAYS CURRENTLY REVIEWING DETAILS OF TEVA’S NOTICE, PARAGRAPH IV CERTIFICATION - SEC FILING.  Full Article

Broadfin Capital Reports 9.99 Pct Passive Stake In Egalet Corp
Wednesday, 3 Jan 2018 04:52pm EST 

Jan 3 (Reuters) - Egalet Corp ::BROADFIN CAPITAL LLC REPORTS A 9.99 PCT PASSIVE STAKE IN EGALET CORP AS OF DEC 27, 2017 - SEC FILING.  Full Article

Egalet Reduces Announces Refinancing Of Existing Convertible Notes
Wednesday, 20 Dec 2017 08:16am EST 

Dec 20 (Reuters) - Egalet Corp ::EGALET REDUCES DEBT OBLIGATION, EXTENDS MATURITY AND LOWERS ANNUAL INTEREST PAYMENTS THROUGH REFINANCING OF EXISTING CONVERTIBLE NOTES.EGALET CORP - ‍ENTERED INTO EXCHANGE AGREEMENTS WITH CERTAIN HOLDERS OF EGALET'S OUTSTANDING 5.50% SENIOR CONVERTIBLE NOTES DUE APRIL 1, 2020​.EGALET CORP - ‍TOTAL FACE VALUE OF COMPANY'S CONVERTIBLE DEBT WILL BE REDUCED FROM $61.0 MILLION TO $48.5 MILLION THROUGH EXCHANGE​.EGALET - TOTAL PRINCIPAL AMOUNT OUTSTANDING OF EXISTING NOTES TO BE REDUCED, MATURITY DATE OF NEW NOTES IS DEC 2024-A 5-YEAR EXTENSION FROM ORIGINAL DATE.  Full Article

Egalet Receives FDA Tentative Approval For Chronic Pain Treatment Drug
Friday, 15 Dec 2017 06:02am EST 

Dec 15 (Reuters) - Egalet Corp ::EGALET RECEIVES FDA TENTATIVE APPROVAL FOR EXPANDED LABEL FOR ARYMO® ER (MORPHINE SULFATE) C-II, AN EXTENDED-RELEASE MORPHINE PRODUCT FORMULATED WITH ABUSE-DETERRENT PROPERTIES FOR TREATMENT OF CHRONIC PAIN.EGALET - FINAL APPROVAL EXPECTED TO BE GRANTED WHEN EXCLUSIVITY PERIOD EXPIRES ON OCT. 2, 2018.EGALET CORP - ‍INTRANASAL ABUSE-DETERRENT CLAIM TO BE ADDED TO ARYMO ER PRESCRIBING INFORMATION LABEL FOR ARYMO ER C-II​.  Full Article

Egalet Corp's Phase 3 Study Of Egalet-002 In Patients With Moderate-To-Severe Chronic Low Back Pain Meets Primary Endpoint​
Tuesday, 28 Nov 2017 06:02am EST 

Nov 28 (Reuters) - Egalet Corp ::EGALET ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY EVALUATING EFFICACY AND SAFETY OF EGALET-002 IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN.EGALET CORP - ‍EGALET-002 WAS GENERALLY WELL-TOLERATED AND NO NEW SAFETY CONCERNS WERE IDENTIFIED IN STUDY​.EGALET CORP - ‍STUDY OF EGALET-002 MET ITS PRIMARY ENDPOINT​.  Full Article

Egalet Corp Says ‍Apotex Has Lost Right To Launch An Authorized Generic Version Of Sprix Nasal Spray​
Monday, 27 Nov 2017 05:35pm EST 

Nov 27 (Reuters) - Egalet Corp ::EGALET CORP - ‍COMPANY DID NOT RECEIVE ANY WRITTEN NOTIFICATION ON OR BEFORE NOTIFICATION DEADLINE FOR PRODUCT LAUNCH FROM APOTEX CORP & APOTEX INC​.EGALET CORP - ‍APOTEX HAS LOST RIGHT TO LAUNCH AN AUTHORIZED GENERIC VERSION OF SPRIX NASAL SPRAY​.EGALET CORP - ‍IF APOTEX IS ABLE TO SATISFY REQUIREMENTS FOR LAUNCHING AN UNAUTHORIZED GENERIC, IT WOULD BE PERMITTED TO DO SO IN SEPTEMBER 2018​.  Full Article

Egalet Q2 loss per share $1.04
Wednesday, 9 Aug 2017 04:02pm EDT 

Aug 9 (Reuters) - Egalet Corp :Egalet announces second quarter 2017 financial results and expense reduction plan.Q2 loss per share $1.04.Says ‍announcing an expense reduction plan that includes a corporate restructuring​.Qtrly net revenue grew to $6.3 million representing increases of 81 percent over q2 of 2016 and 15 percent over Q1 of 2017.Egalet corp says company restructuring expected to reduce costs by 35%.Egalet - reducing workforce, excluding sales team, by nearly 40 percent. With this initiative, along with elimination of certain other expenditures​.Says ‍with the initiative expects total costs and expenses to be between $55 and $60 million in 2018​.Egalet Corp - anticipates that its existing cash, cash equivalents and marketable securities, will enable Egalet to fund its operations into 2020​.Says ‍total net product sales were $6.3 million for quarter ended June 30, 2017 compared to $3.5 million​.  Full Article

Highbridge Capital Management LLC reports 9.58 pct passive stake in Egalet Corp as of July 6 - SEC filing
Monday, 17 Jul 2017 04:58pm EDT 

July 17 (Reuters) - Egalet Corp :Highbridge Capital Management LLC reports a 9.58 percent passive stake in Egalet Corp as of July 6, 2017 - SEC filing.  Full Article

Egalet announces pricing of public offering of common stock and warrants
Thursday, 6 Jul 2017 09:24am EDT 

July 6 (Reuters) - Egalet Corp ::Egalet announces pricing of public offering of common stock and warrants.Says public offering of 16.7 million common shares priced at $1.80per share.  Full Article

BRIEF-Egalet Reports Q1 Loss Per Share $0.26

* EGALET CORP - NET PRODUCT SALES OF $6.3 MLN FOR QUARTER ENDED MARCH 31, 2018 COMPARED TO $5.4 MLN Source text for Eikon: Further company coverage: